Literature DB >> 8345978

Antimicrobial treatment of occult bacteremia: a multicenter cooperative study.

J W Bass1, R W Steele, R R Wittler, M E Weisse, V Bell, A H Heisser, J H Brien, J E Fajardo, G M Wasserman, J M Vincent.   

Abstract

This prospective multicenter study was conducted to define more clearly clinical and laboratory criteria that predict a strong probability of occult bacteremia and to evaluate the effect of empiric broad spectrum antimicrobial treatment of these children. Children 3 to 36 months old with fever > or = 40 degrees C (104 degrees F) or, > or = 39.5 degrees C (103 degrees F) with white blood cells (WBC) > or = 15 x 10(9)/liter, and no focus of infection had blood cultures obtained and were randomized to treatment with oral amoxicillin/potassium clavulanate or intramuscular ceftriaxone. Sixty of 519 (11.6%) study patients had positive blood cultures: Streptococcus pneumoniae, 51; Haemophilus influenzae b, 6; Neisseria meningitidis, 2; and Group B Streptococcus, 1. Subgroups of high risk were identified as fever > or = 39.5 degrees C and WBC > or = 15 x 10(9)/liter, 55 of 331 or 16.6% positive with increasing incidence of positive culture with increasing increments of degrees of leukocytosis to WBC > or = 30 x 10(9)/liter where 9 of 21 or 42.9% were positive. Subgroups of significantly lower risk were identified as fever > or = 39.5 degrees C and WBC < 15 x 10(9)/liter, 5 of 182 or 2.7% positive and those with WBC < 10 x 10(9)/liter, 0 of 99 or 0.0% positive. Children with positive cultures who received ceftriaxone were nearly all afebrile after 24 hours whereas a significant number who received amoxicillin/potassium clavulanate remained febrile. In the 459 culture-negative children more amoxicillin/potassium clavulanate-treated children developed diarrhea and had less improvement in clinical scores after 24 hours than ceftriaxone-treated children.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8345978     DOI: 10.1097/00006454-199306000-00003

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  15 in total

1.  Clinical epidemiological principles in bedside teaching.

Authors:  J G Ruiz; J M Lozano
Journal:  Indian J Pediatr       Date:  2000-01       Impact factor: 1.967

Review 2.  Unexplained fever in young children: how to manage severe bacterial infection.

Authors:  Itzhak Brook
Journal:  BMJ       Date:  2003-11-08

Review 3.  Management of the non-toxic-appearing acutely febrile child: a 21st century approach.

Authors:  Ravi Jhaveri; Carrie L Byington; Jerome O Klein; Eugene D Shapiro
Journal:  J Pediatr       Date:  2011-05-17       Impact factor: 4.406

Review 4.  Rational prescribing of antibacterials in hospitalised children.

Authors:  J E Hoppe
Journal:  Pharmacoeconomics       Date:  1996-12       Impact factor: 4.981

5.  Ceftriaxone. A pharmacoeconomic evaluation of its use in the treatment of serious infections.

Authors:  R Davis; H M Bryson
Journal:  Pharmacoeconomics       Date:  1994-09       Impact factor: 4.981

Review 6.  Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections.

Authors:  Harriet M Lamb; Douglas Ormrod; Lesley J Scott; David P Figgitt
Journal:  Drugs       Date:  2002       Impact factor: 9.546

7.  Evaluation of a protocol for selective empiric treatment of fever without localising signs.

Authors:  G J Browne; J M Ryan; P McIntyre
Journal:  Arch Dis Child       Date:  1997-02       Impact factor: 3.791

Review 8.  Place of parenteral cephalosporins in the ambulatory setting: clinical evidence.

Authors:  D Nathwani
Journal:  Drugs       Date:  2000       Impact factor: 9.546

9.  Oral Is the New IV. Challenging Decades of Blood and Bone Infection Dogma: A Systematic Review.

Authors:  Noah Wald-Dickler; Paul D Holtom; Matthew C Phillips; Robert M Centor; Rachael A Lee; Rachel Baden; Brad Spellberg
Journal:  Am J Med       Date:  2021-10-27       Impact factor: 4.965

10.  Agreement of decision analyses and subsequent clinical studies in infectious diseases.

Authors:  Joshua N Bress; Todd Hulgan; Jennifer A Lyon; Cecilia P Johnston; Harold Lehmann; Timothy R Sterling
Journal:  Am J Med       Date:  2007-05       Impact factor: 4.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.